Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Published byΕὔα Λαμπρόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections."— Presentation transcript:

1 Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.
Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Single-genome envelope amplification was performed with plasma viral RNA on day 28. For one saline control animal, H515, viral amplification failed and therefore is not shown here. The env sequence at the top presents the SHIV-325c molecular clone inoculum. The column on the right reports the frequency of distinct amplicons (based on unique sequence variations in V1V2) per total env amplicons obtained from a given animal. Boris Julg et al., Sci Transl Med 2017;9:eaal1321 Published by AAAS

Download ppt "Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections."

Similar presentations

Deep Sequencing of Patient Genomes for Disease Diagnosis: When Will It Become Routine? by Stephen F. Kingsmore, and Carol J. Saunders Sci Transl Med Volume.

Deep Sequencing of Patient Genomes for Disease Diagnosis: When Will It Become Routine? by Stephen F. Kingsmore, and Carol J. Saunders Sci Transl Med Volume.
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.
Fig. 7. Intrapatient variation in key contact signatures for PGDM1400 and PGT121. Intrapatient variation in key contact signatures for PGDM1400 and PGT121.

Fig. 7. Intrapatient variation in key contact signatures for PGDM1400 and PGT121. Intrapatient variation in key contact signatures for PGDM1400 and PGT121.
Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.
Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.
Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.
Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.

Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.
Fig. 2. Bestatin treatment improves tail anatomy and restores lymphatic function. Bestatin treatment improves tail anatomy and restores lymphatic function.

Fig. 2. Bestatin treatment improves tail anatomy and restores lymphatic function. Bestatin treatment improves tail anatomy and restores lymphatic function.
Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.
Strategy for CRISPR/Cas9-mediated genome editing in ΔEx50 mice

Strategy for CRISPR/Cas9-mediated genome editing in ΔEx50 mice
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.
Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.

Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.
Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.
Fig. 4. Biomechanical properties of treated tibiae.

Fig. 4. Biomechanical properties of treated tibiae.
Fig. 1. Schematic representation of the MANO method.

Fig. 1. Schematic representation of the MANO method.
JQ1 directly represses the promoter activities of BRCA1 and RAD51

JQ1 directly represses the promoter activities of BRCA1 and RAD51

Similar presentations

Ads by Google